CRPC w/ Bone Metastases VL

Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong

Details
Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentia...

Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg

Details
Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...

The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor

Details
Charles Ryan, MD, and Oliver Sartor, MD discuss bone health in the treatment of prostate cancer and then transition to discuss the novel theranostic opportunities that are in development for the treatment of prostate cancer including Lutetium-177 PSMA and Actinium PSMA-225. Lastly, they have a concise conversation about DNA mutations in prostate cancer and the implications of germ-line and somatic...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

Details
(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...

Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer - Phillip Koo

Details
In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer. Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following...